More on Sangamo Q2 results

Sangamo BioSciences (SGMO +6.1%) Q2 results: Total Revenues: $10.4M (+49.8%), Collaboration Agreements: $9.7M (+57.9%); Operating Expenses: $17.4M (+40.6%); Net Loss: ($7.0M) (-28.1%); Quick Assets: $236.7M (+79.6%).

2014 Guidance: Revenues: $45M - 50M; Operating expenses: $65M - 70M; Quick Assets: at least $225M by year end.

From other sites
Comments (1)
  • MineMan
    , contributor
    Comments (557) | Send Message
    webcast worth listening to.
    new hires to move manufacturing and Pre-clinical work forward, aggressively.
    2 INDs to be filed in the summer of 2014.
    many other key points covered, I suggest everyone take the time to listen.
    23 Jul 2014, 06:03 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs